Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
09/2014
09/25/2014US20140286973 Chimeric antigen receptor specific for folate receptor beta
09/25/2014US20140286967 Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma
09/25/2014US20140286965 Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
09/25/2014US20140286964 Methods for Identifying Janus Kinase (JAK) Modulators for Therapeutics
09/25/2014US20140286963 Methods and compositions for neural disease immunotherapy
09/25/2014US20140286962 Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
09/25/2014US20140286961 Novel Methods Of Cancer Therapy Targeted Against A Cancer Stem Line
09/25/2014US20140286960 Staphlococcus aureus alpha-hemolysin antibodies
09/25/2014US20140286959 Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
09/25/2014US20140286958 Interleukin-31 Monoclonal Antibody
09/25/2014US20140286957 ANTIBODIES TO CD1d
09/25/2014US20140286956 Modulating inflammasome activity and inflammation in the central nervous system
09/25/2014US20140286955 Notch agonists for the treatment of cancer
09/25/2014US20140286954 Tau protease compositions and methods of use
09/25/2014US20140286953 Hepcidin, hepcidin antagonists and methods of use
09/25/2014US20140286952 Inhibitors of Metastasis, Methods of Generating Such Inhibitors and Their Therapeutic Applications
09/25/2014US20140286951 Met-binding agents and uses thereof
09/25/2014US20140286950 Use of anti-cd83 agonist antibodies for treating autoimmune diseases
09/25/2014US20140286949 Method of attenuating reactions to skin irritants
09/25/2014US20140286946 Method for preparing antibodies having improved properties
09/25/2014US20140286942 Methods for treating chronic obstructive pulmonary disease
09/25/2014US20140286941 Treatment of tnfalpha related disorders
09/25/2014US20140286940 Treatment of tnfalpha related disorders
09/25/2014US20140286939 Treatment of tnfalpha related disorders
09/25/2014US20140286937 Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
09/25/2014US20140286936 Anti-human cxcr4 antibodies
09/25/2014US20140286935 Antigen binding proteins
09/25/2014US20140286934 Humanized antibodies that bind to cd19 and their uses
09/25/2014US20140286932 Giant Obscurins and Uses Thereof in Cancer Prognosis and Therapy
09/25/2014US20140286898 Interleukin-2 muteins for the expansion of t-regulatory cells
09/25/2014US20140286867 Use of tnfalpha inhibitor for treatment of erosive polyarthritis
09/25/2014US20140286862 Therapeutic Agents and Uses Thereof
09/25/2014US20140286861 RS7 Antibodies
09/25/2014US20140286860 Immunoconjugates with an Intracellularly-Cleavable Linkage
09/25/2014US20140286859 Psma antibodies and uses thereof
09/24/2014EP2781527A1 Immunoassay for cyclopropylindole based synthetic cannabinoids, metabolites and derivatives thereof
09/24/2014EP2781526A1 Bispecific anti-VEGF/anti-ANG-2 antibodies
09/24/2014EP2780719A1 Diagnosis of sepsis and systemic inflammatory response syndrome
09/24/2014EP2780375A1 Binding molecules for bcma and cd3
09/24/2014EP2780374A1 Binding molecules for bcma and cd3
09/24/2014EP2780373A1 Anti il-36r antibodies
09/24/2014EP2780372A1 Bi-specific antibodies for medical use
09/24/2014EP2780371A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
09/24/2014EP2780370A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
09/24/2014EP2780369A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
09/24/2014EP2780368A1 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
09/24/2014EP2780367A1 Antibodies for molecular imaging of vulnerable plaques in atherosclerosis
09/24/2014EP2780366A2 Rsv g protein specific antibodies
09/24/2014EP2780040A1 Methods of treating epidermal growth factor deletion mutant viii related disorders
09/23/2014US8841433 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
09/23/2014US8841425 Cytotoxic agents comprising new maytansinoids
09/23/2014US8841424 Humanized AXL antibodies
09/23/2014US8841423 Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
09/23/2014US8841422 Human androgen receptor alternative splice variants
09/23/2014US8841421 S100A9 interaction screening method
09/23/2014US8841420 Synthetic peptide constructs for the diagnosis and treatment of periodontis associated with Porphyromonas gingivalis
09/23/2014US8841419 Hybridoma cell line 10G4 and a monoclonal antibody against the total of aflatoxin B1, B2, G1 and G2
09/23/2014US8841418 Antibodies that specifically bind to TIM3
09/23/2014US8841417 IL-1 binding proteins
09/23/2014US8841416 Therapeutic nuclease compositions and methods
09/23/2014US8841274 Protein arginine N-methyltransferase-5 method of cancer treatment
09/23/2014US8841238 Methods for producing active scFv antibodies and libraries therefor
09/23/2014US8841136 Levetiracetam immunoassays
09/23/2014US8841108 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
09/23/2014US8841104 Methods for isolating a target analyte from a heterogeneous sample
09/23/2014US8841080 System for determining unprocessed and partially processed neurotoxin type A
09/23/2014US8840906 Methods and compositions related to immunizing against Staphylococcal lung disease and conditions
09/23/2014US8840897 Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (NAIT)
09/23/2014US8840896 Anti-HER2 antibody variants
09/23/2014US8840895 Human antibodies specifically binding to the hepatitis B virus surface antigen
09/23/2014US8840894 Antibodies to human GDF8
09/23/2014US8840893 Methods for treating conditions associated with MASP-2 dependent complement activation
09/23/2014US8840891 Human monoclonal antibodies to the thyrotropin receptor which act as antagonists
09/23/2014US8840890 Rapid expression cloning of human monoclonal antibodies from memory B cells
09/23/2014US8840889 Methods of modulating immune function
09/23/2014US8840888 Dosage regimen for administering a CD19XCD3 bispecific antibody
09/23/2014US8840887 Antibodies
09/23/2014US8840886 Method of treating cancer with DLL4 antagonist and chemotherapeutic agent
09/23/2014US8840885 Methods for treating chronic lymphocytic leukemia
09/23/2014US8840884 Antibody-containing solution pharmaceuticals
09/23/2014US8840877 Polysaccharide-protein conjugates reversibly coupled via imine bonds
09/23/2014CA2691357C Antibodies to human programmed death receptor pd-1
09/23/2014CA2666308C Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
09/23/2014CA2646934C Methods for reducing protein aggregation
09/23/2014CA2638902C Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
09/23/2014CA2548990C Toll-like receptor 4 (tlr4)-neutralizing antibodies
09/23/2014CA2525975C Humanized antibodies that recognize beta amyloid peptide
09/23/2014CA2490758C Dosage form of recombinant humanized monoclonal antibody 2c4
09/23/2014CA2473039C Novel anti-igf-ir antibodies and uses thereof
09/23/2014CA2467781C Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia
09/23/2014CA2378182C Compositions and methods for the treatment of tumors
09/18/2014WO2014145907A1 Targeting t cells with heterodimeric proteins
09/18/2014WO2014145806A2 Heterodimeric proteins
09/18/2014WO2014145735A2 Product and process for mucus viscosity normalization
09/18/2014WO2014145654A1 Method for the site-specific covalent cross-linking of antibodies to surfaces
09/18/2014WO2014145441A1 Sortase-mediated protein purification and ligation
09/18/2014WO2014145208A1 Hydrophobic interaction protein chromatography under no-salt conditions
09/18/2014WO2014145174A1 Immunogenic human rhinovirus (hrv) compositions
09/18/2014WO2014145091A1 Cell culture media and methods of antibody production
09/18/2014WO2014145000A2 Anti-cd25 antibodies and their uses
1 ... 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 ... 1494